New York legislation · 2025-2026 General Assembly
New York S8925: Prohibits the sale of 7-hydroxymitragynine products
Status: Passed both chambers, June 5, 2026
Prohibits the sale of products that contain 7-hydroxymitragynine at a level that exceeds 2% of total alkaloids or one milligram per serving; establishes fines for the sale of such products.
What the bill says
An act to amend the general business law, in relation to prohibiting the sale of 7-hydroxymitragynine products.
From the amended text, May 11, 2026:
AN ACT to amend the general business law, in relation to prohibiting the sale of 7-hydroxymitragynine products THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS: Section 1. The general business law is amended by adding a new section 392-l to read as follows: § 392-L. SALE OF 7-HYDROXYMITRAGYNINE PRODUCTS. 1. FOR PURPOSES OF THIS SECTION, THE TERM "7-HYDROXYMITRAGYNINE PRODUCTS" SHALL MEAN ANY SUBSTANCE, MATERIAL, MIXTURE, COMPOUND, PREPARATION, EXTRACT, OR FINISHED GOODS THAT CONTAINS 7-HYDROXYMITRAGYNINE AT A LEVEL THAT EXCEEDS TWO PERCENT OF TOTAL ALKALOIDS OR ONE MILLIGRAM PER SERVING. 2. THE PROVISIONS OF THIS SECTION SHALL APPLY TO THE SALE, OFFER FOR SALE, DELIVERY, OR DISTRIBUTION OF ALL 7-HYDROXYMITRAGYNINE PRODUCTS. 3. NO CORPORATION, PARTNERSHIP, LIMITED LIABILITY COMPANY, FIRM, ONLINE PLATFORM, OR ANY OTHER BUSINESS ENTITY DOING BUSINESS WITHIN THIS STATE SHALL KNOWINGLY SELL, OFFER FOR SALE, OR DELIVER 7-HYDROXYMITRAGYNINE PRODUCTS. 4. ANY CORPORATION, PARTNERSHIP, LIMITED LIABILITY COMPANY, FIRM, ONLINE PLATFORM, OR OTHER BUSINESS ENTITY DOING BUSINESS WITHIN THIS STATE THAT VIOLATES THE PROVISIONS OF THIS SECTION BY KNOWINGLY SELLING, OFFERING FOR SALE, OR DELIVERING 7-HYDROXYMITRAGYNINE PRODUCTS SHALL BE SUBJECT TO A CIVIL PENALTY OF NOT MORE THAN FIVE HUNDRED DOLLARS FOR A FIRST VIOLATION, AND ONE THOUSAND DOLLARS FOR EACH SUBSEQUENT VIOLATION, RECOVERABLE IN AN ACTION BY THE ATTORNEY GENERAL OF …
Sponsors
- Ryan, Christopher (D, 50) · primary sponsor
- Jacob Ashby (R, 43)
- Patricia Fahy (D, 46)
- Peter Harckham (D, 40)
- Dean Murray (R, 3)
- Anthony Palumbo (R, 1)
- Steven Rhoads (R, 5)
Latest actions
- : RETURNED TO SENATE
- : PASSED ASSEMBLY
- : ORDERED TO THIRD READING RULES CAL.408
- : SUBSTITUTED FOR A9156B
- : REFERRED TO WAYS AND MEANS
- : DELIVERED TO ASSEMBLY
- : PASSED SENATE
- : ADVANCED TO THIRD READING
- : 2ND REPORT CAL.
- : 1ST REPORT CAL.1297
Votes
- FLOOR Vote (June 2, 2026): 61 yea, 0 nay, passed
- Senate Consumer Protection Committee: COMMITTEE Vote (May 20, 2026): 7 yea, 0 nay, passed
- Consumer Protection Committee Vote (May 20, 2026): 7 yea, 0 nay, passed
Subjects: General Business Law
Common questions
- What is S8925?
- S8925 is a bill in the New York Legislature (2025-2026 General Assembly): Prohibits the sale of 7-hydroxymitragynine products.
- What does S8925 do?
- In its own words: An act to amend the general business law, in relation to prohibiting the sale of 7-hydroxymitragynine products.
- What is the status of S8925?
- Passed both chambers as of June 5, 2026. Latest action: RETURNED TO SENATE (June 5, 2026).
- Who sponsored S8925?
- Ryan, Christopher (D, 50), with 6 co-sponsors.
- Where is the official record for S8925?
- On the New York Legislature website: https://www.nysenate.gov/legislation/bills/2025/S8925
Source: official New York record. Tracked by Delilah, AI for legislation across all 50 states and Congress.